相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours
Maja de Jonge et al.
EUROPEAN JOURNAL OF CANCER (2017)
A phase I study of the MDM2 inhibitor AMG 232 in patients with advanced p53 wild type (p53WT) solid tumors or multiple myeloma
M. H. Langenberg et al.
EUROPEAN JOURNAL OF CANCER (2016)
Dose- and regimen-finding phase I study of NVP-HDM201 in patients (pts) with TP53 wild-type (wt) advanced tumors
D. Hyman et al.
EUROPEAN JOURNAL OF CANCER (2016)
TP53 mutations emerge with HDM2 inhibitor SAR405838 treatment in de-differentiated liposarcoma
Joonil Jung et al.
NATURE COMMUNICATIONS (2016)
P53 activation inhibits all types of hematopoietic progenitors and all stages of megakaryopoiesis
Emna Mahfoudhi et al.
ONCOTARGET (2016)
Phase I study of FOLFIRI plus pimasertib as second-line treatment for KRAS-mutated metastatic colorectal cancer
T. Macarulla et al.
BRITISH JOURNAL OF CANCER (2015)
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumors
V. De Weger et al.
EUROPEAN JOURNAL OF CANCER (2015)
Clinical, pharmacokinetic and pharmacodynamic data for the MEK1/2 inhibitor pimasertib in patients with advanced hematologic malignancies
F. Ravandi et al.
BLOOD CANCER JOURNAL (2015)
Activation of p53 by the MDM2 inhibitor RG7112 impairs thrombopoiesis
Camelia Iancu-Rubin et al.
EXPERIMENTAL HEMATOLOGY (2014)
Safety and Recommended Phase II Dose (RP2D) of the Selective Oral MEK1/2 Inhibitor Pimasertib (MSC1936369B/AS703026): Results of a Phase I Trial
A. Awada et al.
EUROPEAN JOURNAL OF CANCER (2012)
Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study
Isabelle Ray-Coquard et al.
LANCET ONCOLOGY (2012)
TP53 Mutations in Human Cancers: Origins, Consequences, and Clinical Use
Magali Olivier et al.
COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY (2010)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
Targeting mitogen-activated protein kinase kinase (MEK) in solid tumors
Austin Duffy et al.
TARGETED ONCOLOGY (2009)
The first 30 years of p53: growing ever more complex
Arnold J. Levine et al.
NATURE REVIEWS CANCER (2009)
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2
LT Vassilev et al.
SCIENCE (2004)
Targeting the mitogen-activated protein kinase cascade to treat cancer
JS Sebolt-Leopold et al.
NATURE REVIEWS CANCER (2004)
Targeting ras signalling pathways in cancer therapy
J Downward
NATURE REVIEWS CANCER (2003)
分享论文
